Clinical and molecular analysis of macrolide resistance in Mycobacterium avium complex lung disease

American Journal of Respiratory and Critical Care Medicine

Volumn 174, Issue 8, 2006, Pages 928-934

  Griffith, David E ^a   Brown Elliott, Barbara A ^b   Langsjoen, Brett ^b   Zhang, Yansheng ^b   Pan, Xi ^b   Girard, William ^b   Nelson, Kenwyn ^b   Caccitolo, James ^b   Alvarez, Julio ^b   Shepherd, Sara ^b   Wilson, Rebecca ^b   Graviss, Edward A ^b   Wallace Jr , Richard J ^b  

^a Health Science Center   (United States)

^b NONE

Author keywords

Aminoglycosides; Sequencing mutations; Surgery

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; AZITHROMYCIN; CLARITHROMYCIN; CLOFAZIMINE; ETHAMBUTOL; ETHIONAMIDE; GAMMA INTERFERON; LINEZOLID; MACROLIDE; QUINOLONE; QUINOLONE DERIVATIVE; RIFABUTIN; RIFAMPICIN; RIFAMYCIN DERIVATIVE; STREPTOMYCIN;

ADULT; AGED; BRONCHIECTASIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA SEQUENCE; DRUG BLOOD LEVEL; DRUG SAFETY; FEMALE; HUMAN; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MYCOBACTERIUM INTRACELLULARE; MYCOBACTERIUM INTRACELLULARE AVIUM; OTOTOXICITY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RNA SEQUENCE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

AGED; ANTI-INFECTIVE AGENTS; BACTERIAL PROTEINS; CHAPERONINS; CLARITHROMYCIN; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; MACROLIDES; MALE; MIDDLE AGED; MYCOBACTERIUM AVIUM COMPLEX; MYCOBACTERIUM AVIUM-INTRACELLULARE INFECTION; PNEUMONIA, BACTERIAL; POLYMERASE CHAIN REACTION; PROGNOSIS; RETROSPECTIVE STUDIES; RNA, BACTERIAL;

EID: 33749827403     PISSN: 1073449X     EISSN: 1073449X     Source Type: Journal    
DOI: 10.1164/rccm.200603-450OC     Document Type: Review

References (47)

1. Wallace RJ Jr, Brown BA, Griffith DE, Girard WM, Murphy DT, Onyi GO, Steingrube VA, Mazurek GH. Initial clarithromycin monotherapy for Mycobacterium avium-intracellulare complex lung disease. Am J Respir Crit Care Med 1994;149:1335-1341.
2. Griffith DE, Brown BA, Girard WM, Murphy DT, Wallace RJ Jr. Azithromycin activity against Mycobacterium avium complex lung disease in patients who were not infected with human immunodeficiency virus. Clin Infect Dis 1996;23:983-989.
3. Wallace RJ Jr, Brown BA, Griffith DE, Girard WM, Murphy DT. Clarithromycin regimens for pulmonary Mycobacterium avium complex: the first 50 patients. Am J Respir Crit Care Med 1996;153:1766-1772.
4. Griffith DE, Brown BA, Murphy DT, Girard WM, Couch L, Wallace RJ Jr. Initial (6 month) results of three-times-weekly azithromycin in treatment regimens for Mycobacterium avium complex lung disease in human immunodeficiency virus-negative patients. J Infect Dis 1998;178:121-126.
5. Griffith DE, Brown BA, Cegielski P, Murphy DT, Wallace RJ Jr. Early results (at 6 months) with intermittent clarithromycin-including regimens for lung disease due to Mycobacterium avium complex. Clin Infect Dis 2000;30:288-292.
6. Griffith DE, Brown BA, Girard WM, Griffith BE, Couch LA, Wallace RJ Jr. Azithromycin-containing regimens for treatment of Mycobacterium avium complex lung disease. Clin Infect Dis 2001;32:1547-1553.
7. Griffith DE, Brown-Elliott BA, Wallace RJ Jr. Macrolide-resistant Mycobacterium avium complex (MAC) lung disease [abstract]. Am J Respir Crit Care Med 2003;167:A434.
8. Wallace RJ Jr, Cook JL, Glassroth J, Griffith DE, Olivier KN, Gordin F. Diagnosis and treatment of disease caused by nontuberculous mycobacteria. American Thoracic Society Statement. Am J Respir Crit Care Med 1997;156:S1-S25.
9. Brown BA, Wallace RJ Jr, Onyi GO. Activities of clarithromycin against eight slowly growing species of nontuberculous mycobacteria, determined by using a broth microdilution MIC system. Antimicrob Agents Chemother 1992;36:1987-1990.
10. National Committee for Clinical Laboratory Standards. Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes. Approved Standard. NCCLS document M24-A, 2003.
11. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005;353:487-497.
12. Nelson KG, Griffith DE, Brown BA, Wallace RJ Jr. Results of operation in Mycobacterium avium-intracellulare lung disease. Ann Thorac Surg 1998;66:325-330.
13. Griffith DE, Brown-Elliott BA, Shepherd S, McLarty J, Griffith L, Wallace RJ Jr. Ethambutol ocular toxicity in treatment regimens for Mycobacterium avium complex lung disease. Am J Respir Crit Care Med 2005;172:250-253.
14. Wallace RJ Jr, Zhang Y, Brown-Elliott BA, Yakrus MA, Wilson RW, Mann L, Couch L, Girard WM, Griffith DE. Repeat positive cultures in Mycobacterium intracellulare lung disease after macrolide therapy represent new infections in patients with nodular bronchiectasis. J Infect Dis 2002;186:266-273.
15. Mazurek GH, Hartman S, Zhang Y-S, Brown BA, Hector JSR, Murphy D, Wallace RJ Jr. Large DNA restriction fragment polymorphism in the Mycobacterium avium-M. intracellulare complex: a potential epidemiologic tool. J Clin Microbiol 1993;31:390-394.
16. Wallace RJ Jr, Zhang Y, Brown BA, Dawson D, Murphy DT, Wilson R, Griffith DE. Polyclonal Mycobacterium avium complex infections in patients with nodular bronchiectasis. Am J Respir Crit Care Med 1998;158:1235-1244.
17. Telenti A, Marchesi F, Balz M, Bally F, Böttger EC, Bodmer T. Rapid identification of mycobacteria to the species level by polymerase chain reaction and restriction enzyme analysis. J Clin Microbiol 1993;31:175-178.
18. Smole SC, McAleese F, Ngampasutadol J, von Reyn CF, Arbeit RD. Clinical and epidemiological correlates of genotypes within the Mycobacterium avium complex defined by restriction and sequence analysis of hsp65. J Clin Microbiol 2002;40:3374-3380.
19. Heifets L. Clarithromycin against Mycobacterium avium complex isolates. Tuber Lung Dis 1996;77:19-26.
20. Heifets L, Mor N, Vanderkolk J. Mycobacterium avium strains resistant to clarithromycin and azithromycin. Antimicrob Agents Chemother 1993;37:2364-2370.
21. Tenover FC, Arbeit RD, Goering RV, Mickelsen PA, Murray BE, Persing DH, Swaminathan B. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol 1995;33:2233-2239.
22. Dutt AK, Stead WW. Long-term results of medical treatment in Mycobacterium intracellulare infection. Am J Med 1979;67:449-453.
23. Rosenzweig DY. Pulmonary mycobacterial infections due to Mycobacterium intracellulare-avium complex: clinical features and course in 100 consecutive cases. Chest 1979;75:115-119.
24. Yeager H Jr, Raleigh JW. Pulmonary disease due to Mycobacterium intracellulare. Am Rev Respir Dis 1973;108:547-552.
25. Dhillon SS, Watanakunakorn C. Lady Windermere syndrome: middle lobe bronchiectasis and Mycobacterium avium complex infection due to voluntary cough suppression. Clin Infect Dis 2000;30:572-575.
26. Huang JH, Kao PN, Adi V, Ruoss SJ. Mycobacterium avium-intracellulare pulmonary infection in HIV-negative patients without preexisting lung disease. Chest 1999;115:1033-1040.
27. Kennedy TP, Weber DJ. Nontuberculous mycobacteria: an underappreciated cause of geriatric lung disease. Am J Respir Crit Care Med 1994;149:1654-1658.
28. Reich JM, Johnson RE. Mycobacterium avium complex pulmonary disease. Am Rev Respir Dis 1991;143:1381-1385.
29. Meier A, Kirschner P, Springer B, Steingrube VA, Brown BA, Wallace RJ Jr, Böttger EC. Identification of mutations in 23S rRNA gene of clarithromycin-resistant Mycobacterium intracellulare. Antimicrob Agents Chemother 1994;38:381-384.
30. Nash KA, Inderlied CB. Genetic basis of macrolide resistance in Mycobacterium avium isolated from patients with disseminated disease. Antimicrob Agents Chemother 1995;39:2625-2630.
31. Meier A, Heifets L, Wallace RJ Jr, Zhang Y, Brown BA, Sander P, Böttger EC. Molecular mechanisms of clarithromycin resistance in Mycobacterium avium: observation of multiple 23S rDNA mutations in a clonal population. J Infect Dis 1996;174:354-360.
32. Bermudez LE, Petrofsky M, Kolonoski P, Young LS. Emergence of Mycobacterium avium populations resistant to macrolides during experimental chemotherapy. Antimicrob Agents Chemother 1998;42:180-183.
33. Vester B, Douthwaite S. Macrolide resistance conferred by base substitutions in 23S rRNA. Antimicrob Agents Chemother 2001;45:1-12.
34. Douthwaite S, Aagaard C. Erythromycin binding is reduced in ribosomes with conformational alterations in the 23S rRNA peptidyl transferase loop. J Mol Biol 1993;232:725-731.
35. Field SK, Cowie RL. Treatment of Mycobacterium avium-intracellulare complex lung disease with a macrolide, ethambutol, and clofazimine. Chest 2003;124:1482-1486.
36. Tanaka E, Kimoto T, Tsuyuguchi K, Watanabe I, Matsumoto H, Niimi A, Suzuki K, Murayama T, Amitani R, Kuze F. Effect of clarithromycin regimen for Mycobacterium avium complex pulmonary disease. Am J Respir Crit Care Med 1999;160:866-872.
37. Cynamon MH, Klemens SP, Grossi MA. Comparative activities of azithromycin and clarithromycin against Mycobacterium avium infection in beige mice. Antimicrob Agents Chemother 1994;38:1452-1454.
38. Ji B, Lounis N, Truffot-Pernot C, Grosset J. Selection of resistant mutants of Mycobacterium avium in beige mice by clarithromycin monotherapy. Antimicrob Agents Chemother 1992;36:2839-2840.
39. Chaisson RE, Benson CA, Dube MP, Heifits LB, Krovick JS, Elkin S, Smith T, Craft JC, Sattler FR, and the Aids Clinical Trial Group Protocol 157 Study Team. Clarithromycin therapy for bacteremic Mycobacterium avium complex disease: a randomized, double-blind, dose ranging study in patients with AIDS. Ann Intern Med 1994;121:905-911.
40. Bermudez LE, Nash KA, Petrofsky M, Young LS, Inderlied CB. Effect of ethambutol on emergence of clarithromycin-resistant Mycobacterium avium complex in the beige mouse model. J Infect Dis 1996;174:1218-1222.
41. Gordin FM, Sullam PM, Shafran SD, Cohn DL, Wynne B, Paxton L, Perry K, Horsburgh CR Jr. A randomized, placebo-controlled study of rifabutin added to a regimen of clarithromycin and ethambutol for treatment of disseminated infection with Mycobacterium avium complex. Clin Infect Dis 1999;28:1080-1085.
42. Benson CA, Williams PL, Currier JS, Holland F, Mahon LF, MacGregor RR, Inderlied CB, Flexner C, Neidig J, Chaisson R, Notario GF, Hafner R, and the AIDS Clinical Trial Group 223 Protocol Team. A prospective, randomized trial examining the efficacy and safety of clarithromycin in combination with ethambutol, rifabutin, or both for the treatment of disseminated Mycobacterium avium complex disease in persons with acquired immunodeficiency syndrome. Clin Infect Dis 2003;37:1234-1243.
43. Lam PK, Griffith DE, Aksamit TR, Ruoss SJ, Garay SM, Daley CL, Catanzavo A. Factors related to response to intermittent treatment of Mycobacterium avium complex lung disease. Am J Respir Crit Care Med 2006;173:1283-1289.
44. Wallace RJ Jr, Brown BA, Griffith DE, Girard W, Tanaka K. Reduced serum levels of clarithromycin in patients with multidrug regimens including rifampin or rifabutin for Mycobacterium avium-M. intracellulare infection. J Infect Dis 1995;171:747-750.
45. Bermudez LE, Nash KA, Petrofsky M, Young LS, Inderlied CB. Clarithromycin-resistant Mycobacterium avium is still susceptible to treatment with clarithromycin and is virulent in mice. Antimicrob Agents Chemother 2000;44:2619-2622.
46. Han XY, Tarrand JJ, Infante R, Jacobson KL, Truong M. Clinical significance and epidemiologic analyses of Mycobacterium avium and Mycobacterium intracellulare among patients without AIDS. J Clin Microbiol 2005;43:4407-4412.
47. Chan ED, Laurel V, Strand MJ, Chan JF, Huynh ML, Goble M, Iseman MD. Treatment and outcome analysis of 205 patients with multidrug resistant tuberculosis. Am J Respir Crit Care Med 2004;169:1103-1109.